U.S. Markets closed
  • S&P 500

    4,008.01
    -15.88 (-0.39%)
     
  • Dow 30

    32,223.42
    +26.76 (+0.08%)
     
  • Nasdaq

    11,662.79
    -142.21 (-1.20%)
     
  • Russell 2000

    1,783.43
    -9.24 (-0.52%)
     
  • Crude Oil

    114.15
    -0.05 (-0.04%)
     
  • Gold

    1,824.50
    +10.50 (+0.58%)
     
  • Silver

    21.64
    +0.09 (+0.41%)
     
  • EUR/USD

    1.0440
    +0.0001 (+0.0104%)
     
  • 10-Yr Bond

    2.8770
    -0.0580 (-1.98%)
     
  • Vix

    27.47
    -1.40 (-4.85%)
     
  • GBP/USD

    1.2325
    +0.0001 (+0.0074%)
     
  • USD/JPY

    128.9620
    -0.0910 (-0.0705%)
     
  • BTC-USD

    30,046.52
    -1,053.42 (-3.39%)
     
  • CMC Crypto 200

    667.04
    +424.36 (+174.87%)
     
  • FTSE 100

    7,464.80
    +46.65 (+0.63%)
     
  • Nikkei 225

    26,547.05
    +119.40 (+0.45%)
     

UPDATE 1-Dr Reddy's to launch generic COVID-19 Merck drug at about 50 cents a pill

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Adds quote from statement, background)

BENGALURU, Jan 4 (Reuters) - Indian drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday.

The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to 1,400 rupees ($18.77). In comparison, the treatment with Merck's pill in the United States costs $700.

"Molflu is expected to be available from early next week in pharmacies throughout (India) with particular focus on states with high caseload of COVID-19," the company spokesperson said.

India last week gave emergency use approval to molnupiravir along with two vaccines, as the country braces for a possible spike in coronavirus cases due to the rapidly spreading Omicron variant.

The South Asian nation reported 37,379 new COVID-19 cases on Tuesday, its highest since early September.

With a view to turn India into a manufacturing hub, Merck has entered into licensing agreements with eight domestic drugmakers, including Dr Reddy's, to make and supply generic versions of molnupiravir to over 100 low- and middle- income countries.

A total of 13 companies in India will make molnupiravir, the country's health minister said last week.

Governments around the world have been scrambling to buy a similar but more effective antiviral treatment from Pfizer , while Merck's pill has faced some setbacks after disappointing trial data. ($1 = 74.5800 Indian rupees) (Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Shinjini Ganguli)